Ascelia Pharma Debt / Assets

What does Ascelia Pharma do? Ascelia Pharma AB develops pharmaceutical products for cancer treatment, focusing on underappreciated drug candidates. The company's pipeline includes Mangoral, a medical imaging drug for liver MRI in patients with impaired kidneys, which has completed phase II clinical trials, and Oncoral, a tablet formulation of irinotecan for gastric cancer treatment, currently in phase I development. Ascelia generates revenue through the development and potential commercialization of these drug candidates, targeting oncology markets with unmet medical needs. The firm identifies and acquires derisked investigational drug candidates, aiming to make them available to cancer patients. Mangoral addresses liver metastases detection in impaired kidney patients, while Oncoral targets gastric cancer treatment. Ascelia's business model relies on advancing these candidates through clinical trials to secure partnerships or regulatory approvals for market entry. Ascelia Pharma AB is headquartered in Malmö, Skåne, and employs 24 full-time staff. The company went public via IPO on March 13, 2019. Its revenue model centers on progressing its pipeline to attract potential partners or buyers for its drug candidates, with no mention of current sales or external funding sources beyond the IPO. Ascelia Pharma is one of the most popular companies on Eulerpool.